Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) has provided an update.
ResMed’s chairman and chief executive officer, Michael J. Farrell, reported changes in his beneficial ownership of the company’s common stock following the exercise of stock options and subsequent sale of shares executed under a pre-arranged Rule 10b5-1 trading plan adopted in October 2024. Farrell exercised options to acquire 4,991 shares at an exercise price of $146.34 per share and then sold the same number of shares at a weighted average price of approximately $248.46, leaving him with 466,223 shares held directly and additional shares held indirectly through a family trust, a routine insider transaction that modestly adjusts but maintains a substantial equity stake in the company’s leadership alignment with shareholders.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. is a global medical technology company specializing in cloud-connected devices and software for the diagnosis, treatment and management of sleep apnea and other chronic respiratory conditions, with its shares traded in the United States under the ticker RMD.
Average Trading Volume: 1,168,910
Technical Sentiment Signal: Buy
Current Market Cap: A$54.89B
For detailed information about RMD stock, go to TipRanks’ Stock Analysis page.